A company press release
concerning an agreement to develop additional research efforts in the search for pharmaceutical treatments for brain tumors:
CombinatoRx and ABC2 Initiate Brain Cancer Collaboration: Partnership Speeds Search for Brain Cancer Cure
Monday September 27, 8:33 am ET
BOSTON and BURLINGAME, Calif., Sept. 27 /PRNewswire/ -- CombinatoRx, Incorporated, a privately held pharmaceutical company, and Accelerate Brain Cancer Cure (ABC2), a non-profit foundation dedicated to accelerating therapies leading to a cure for brain cancer, today announced that they have initiated a research collaboration aimed at identifying novel multi-target drugs for the treatment of brain cancer.
The sponsored research will leverage the CombinatoRx proprietary combination high throughput screening (cHTS) platform in an effort to discover novel drug combinations that hit multiple targets relevant to glioblastoma multiforme (GBM), a deadly form of brain cancer. The cHTS platform allows CombinatoRx to uncover synergistic activities of drug combinations acting on a network of molecular pathways.
[ ... Read the full press release ... ]